The pandemic brought upon by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has upended the global community, infecting over 180 million people and claiming close to 4 million lives in its wake (as of Jul 2021). Although symptoms are typically mild, a small percentage of infected individuals require hospitalization due to severe disease progression. Of those hospitalized in the US, approximately 10% of COVID patients die. Hospitalized COVID-19 patients can face life-threatening pulmonary complications (acute respiratory distress syndrome, acute lung injury) along with extrapulmonary organ failure (acute renal failure, acute cardiac injury). It is increasingly clear that many of these disease processes are manifestations of immunopathology involving hyperinflammatory states. To this end, we sought to identify and assess whether inflammatory biomarkers could predict clinical outcomes in COVID patients. In a cohort of 1831 COVID patients admitted to UCLA, we found that elevated C-reactive protein, procalcitonin, IL-6, D-dimer, and ferritin levels were associtated with mortality. We also tracked changes in immune composition among our cohort and found that eosionophil and lymphocyte recovery during hospitalization correlated with increased survival.